Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
John R. Teerlink(San Francisco VA Medical Center), Gad Cotter(Momentum Research), Beth A. Davison(Momentum Research), G. Michael Felker(Duke University), Gerasimos Filippatos(University General Hospital Attikon), Barry Greenberg(University of California, San Diego), Piotr Ponikowski(Wroclaw Medical University), Elaine Unemori, Adriaan A. Voors(University of Groningen), Kirkwood F. Adams(University of North Carolina at Chapel Hill), Maria I. Dorobantu(Clinical Emergency Hospital Bucharest), Liliana Grinfeld(University of Buenos Aires), Guillaume Jondeau(Hôpital Bichat-Claude-Bernard), Alon Marmor(Rebecca Sieff Hospital), Josep Masip(Universitat de Barcelona), Peter S. Pang(Northwestern University), Karl Werdan(Martin Luther University Halle-Wittenberg), Sam L. Teichman, Angelo J. Trapani(Novartis (United States)), Christopher Bush(Novartis (United States)), Rajnish Saini(Novartis (United States)), Christoph Schumacher(Novartis (Switzerland)), Thomas M. Severin(Novartis (Switzerland)), Marco Metra(University of Brescia)
Cited by 903
Abstract
Related Papers
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
Cathal O’Connor, Randall C. Starling, Adrian F. Hernandez et al.|New England Journal of Medicine|2011|1.2k